3D-CONFORMAL RADIATION THERAPY IN THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CANCER

Alexey V. Nazarenko; Sevil B. Alieva; Sergey I. Tkachev; S. V Medvedev; Denis S. Romanov; V. V Breder; I. V Sagaydak; B. M Medvedeva; Ksenia A. Romanova; O. S Zaychenko; I. P Jazhgunovich; D. I Fedoseenko

doi:10.18821/1028-9984-2019-24-1-2-4-9

Russian Journal of Oncology ›› 2019, Vol. 24 ›› Issue (1-2) : 4 -9. DOI: 10.18821/1028-9984-2019-24-1-2-4-9

Articles

research-article

3D-CONFORMAL RADIATION THERAPY IN THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CANCER

Author information +

History +

PDF

Abstract

Despite the wide possibilities of applying various methods of local and systemic treatment and their continuous improvement, the results of treatment of patients with hepatocellular cancer in general remain unsatisfactory. Based on the latest achievements of science and technology, modern radiation therapy can be used as an effective method of local exposure to liver tumors because of its relative effectiveness and acceptable tolerability. Radiation treatment in the mode of stereotactic body radiation therapy is a promising direction in the complex treatment of patients with hepatocellular carcinoma. It makes it possible to apply ablative doses with a significant reduction of the doses on healthy organs and tissues in a short period of time and the combination of this technique with other approaches of antitumor treatment.

Keywords

hepatocellular carcinoma / 3D-conformal radiation therapy / stereotactic body radiation therapy

Cite this article

Download citation ▾

Alexey V. Nazarenko, Sevil B. Alieva, Sergey I. Tkachev, S. V Medvedev, Denis S. Romanov, V. V Breder, I. V Sagaydak, B. M Medvedeva, Ksenia A. Romanova, O. S Zaychenko, I. P Jazhgunovich, D. I Fedoseenko. 3D-CONFORMAL RADIATION THERAPY IN THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CANCER. Russian Journal of Oncology, 2019, 24(1-2): 4-9 DOI:10.18821/1028-9984-2019-24-1-2-4-9

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142 (6): 1264-1273. DOI: 10.1053/j.gastro.2011.12.061.

[2]	Meyer J., Shefter T.E. Radiation Therapy for Liver Tumors. Springer. 2017. p. 180.

[3]	Belghiti J., Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB: Official J. Int. Hepato. Pancreato. Biliary Assoc. 2005; 7 (1): 42-9. DOI: 10.1080/13651820410024067.

[4]	Lam V.W., Ng K.K., Chok K.S., Yuen J., Tung J., Tso W.K., Fan S.T., Poon R.T. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J. Am. Coll. Surg. 2008; 207 (1): 20-9. DOI: 10.1016/j.jamcollsurg.2008.01.020.

[5]

Sherman M., Burak K., Maroun J., Metrakos P., Knox J.J., Myers R.P., Guindi M., Porter G., Kachura J.R., Rasuli P., Gill S., Ghali P., Chaundhury P., Siddiqui J., Valenti D., Weiss A., Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr. Oncol. 2011; 18 (5): 228-40.

[6]	Goldberg S.N., Hahn P.F., Tanabe K.K., Mueller P.R., Schima W., Athanasoulis C.A., Compton C.C., Solbiati L., Gazelle G.S. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J. Vasc. Interv. Radiol. 1998; 9 (1 Pt 1): 101-11.

[7]	Head H.W., Dodd G.D. 3rd, Dalrymple N.C., Prasad S.R., El-Merhi F.M., Freckleton M.W., Hubbard L.G. Percutaneous radiofrequency ablation of hepatic tumors against the diaphragm: frequency of diaphragmatic injury. Radiology. 2007; 243 (3): 877-84. DOI: 10.1148/radiol.2433060157.

[8]

Stigliano R., Marelli L., Yu D., Davies N., Patch D., Burroughs A.K. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat. Rev. 2007; 33 (5): 437-47. DOI: 10.1016/j.ctrv.2007.04.001.

[9]	Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53 (3): 1020-2. DOI: 10.1002/hep.24199.

[10]	NCCN Guidelines Version 1. 2018. Hepatocellular Carcinoma.

[11]

Ben-Josef E., Normolle D., Ensminger W.D., Walker S., Tatro D., Ten Haken R.K., Knol J., Dawson L.A., Pan C., Lawrence T.S. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J. Clin. Oncol. 2005; 23 (34): 8739-47. DOI: 10.1200/JCO.2005.01.5354.

[12]

Liu M.T., Li S.H., Chu T.C., Hsieh C.Y., Wang A.Y., Chang T.H., Pi C.P., Huang C.C., Lin J.P. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn. J. Clin.Oncol. 2004; 34 (9): 532-9.

[13]	Liang S.X., Zhu X.D., Lu H.J., Pan C.Y., Li F.X., Huang Q.F., Wang A.Y., Chen L., Fu X.L., Jiang G.L. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer. 2005; 103 (10): 2181-8. DOI: 10.1002/cncr.21012.

[14]

Kim T.H., Kim D.Y., Park J.W., Kim Y.I., Kim S.H., Park S.H., Lee W.J., Park S.J., Hong E.K., Kim C.M. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am. J. Clin. Oncol. 2006; 29 (6): 568-75. DOI: 10.1097/01.coc.0000239147.60196.11.

[15]

Seong J., Lee I.J., Shim S.J., Lim D.H., Kim T.H., Kim J.H., Jang H.S., Kim M.S., Chie E.K., Kim J.H., Nam T.K., Lee H.S., Han C.J. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int. 2009; 29 (2): 147-52. DOI: 10.1111/j.1478-3231.2008.01873.x.

[16]

Bibault J.E., Dewas S., Vautravers-Dewas C., Hollebecque A., Jarraya H., Lacornerie T., Lartigau E., Mirabel X. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS ONE. 2013; 8 (10): e77472. DOI: 10.1371/journal.pone.0077472

[17]

Bujold A., Massey C.A., Kim J.J., Brierley J., Cho C., Wong R.K., Dinniwell R.E., Kassam Z., Ringash J., Cummings B., Sykes J., Sherman M., Knox J.J., Dawson L.A. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J. Clin. Oncol. 2013; 31 (13): 1631-1639. DOI: 10.1200/JCO.2012.44.1659.

[18]

Huertas A., Baumann A.S., Saunier-Kubs F., Salleron J., Oldrini G., Croise-Laurent V., Barraud H., Avav A., Bronowicki J.P., Peiffert D. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother. Oncol. 2015; 115 (2): 211-6. DOI: 10.1016/j.radonc.2015.04.006.

[19]

Jang W.I., Kim M.S., Bae S.H., Cho C.K., Yoo H.J., Seo Y.S., Kang J.K., Kim S.Y., Lee D.H., Han C.J., Kim J., Park S.C., Kim S.B., Cho E.H., Kim Y.H. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat. Oncol. 2013; 8: 250. DOI: 10.1186/1748-717X-8-250.

[20]	Sanuki N., Takeda A., Oku Y., Mizuno T., Aoki Y., Eriguchi T., Iwabuchi S., Kunieda E. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol. 2014; 53 (3): 399-404. DOI: 10.3109/0284186X.2013.820342.

[21]

Yamashita H., Onishi H., Murakami N., Matsumoto Y., Matsuo Y., Nomiya T., Nakagawa K.; Japanese Radiological Society multi-institutional SBRT study group (JRS-SBRTSG). Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J. Radiat Res. 2015; 56 (3): 561-7. DOI: 10.1093/jrr/rru130.

[22]

Yoon S.M., Lim Y.S., Park M.J., Kim S.Y., Cho B., Shim J.H., Kim K.M., Lee H.C., Chung Y.H., Lee Y.S., Lee S.G., Lee Y.S., Park J.H., Kim J.H. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS ONE. 2013; 8 (11): e79854. DOI: 10.1371/journal.pone.0079854.

[23]	Wahl D.R., Stenmark M.H., Tao Y., Pollom E.L., Caoili E.M., Lawrence T.S., Schipper M.J., Feng M. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J. Clin. Oncol. 2016; 34 (5): 452-9. DOI: 10.1200/JCO.2015.61.4925.

[24]

Sapir E., Tao Y., Schipper M.J., Bazzi L., Novelli P.M., Devlin P., Owen D., Cuneo K.C., Lawrence T.S., Parikh N.D., Feng M. Stereotactic Body Radiotherapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2017; 100 (1): 122-130. DOI: 10.1016/j.ijrobp.2017.09.001.

[25]	Seong J., Koom W.S., Park H.C. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int. 2005; 25 (2): 261-5. DOI: 10.1111/j.1478-3231.2005.01094.x.

[26]

Soliman H., Ringash J., Jiang H., Singh K., Kim J., Dinniwell R., Brade A., Wong R., Brierley J., Cummings B., Zimmermann C., Dawson L.A. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J. Clin. Oncol. 2013; 31 (31): 3980-3986. DOI: 10.1200/JCO.2013.49.9202.